Answers are grounded in this paper and cite their sources.
Viewpoint proposes a framework to detect cefepime neurotoxicity in critical care, enhancing safety while maintaining efficacy.
Cefepime-induced neurotoxicity (CIN) remains under-recognized despite being a largely exposure-driven and multifactorial complication in neurocritical care. Early identification is often hindered by limited clinical evaluability, delayed electroencephalography (EEG) access, and rapidly evolving renal function that compromises dosing accuracy. Although higher cefepime exposure is consistently associated with increased neurotoxicity risk, no universally accepted therapeutic range clearly separates efficacy from toxicity across critically ill populations. This Viewpoint proposes an anticipatory approach integrating pharmacokinetic principles, therapeutic drug monitoring (TDM), and simplified neuromonitoring to facilitate earlier detection and prevent progression to severe encephalopathy or nonconvulsive seizures. We outline a pragmatic framework to enhance neurological safety while preserving antimicrobial efficacy.
No takes yet. Share an insight, caveat, or question.
Barrasa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: